Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies

Bruce J. Gould, Michael J. Borowitz, Eric S. Groves, Peter W. Carter, Douglas Anthony, Louis M. Weiner, Arthur E. Frankel

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

260F9 Monoclonal antibody-recombinant ricin A chain, an immunotoxin reactive with ≈50% of breast carcinomas, was given by continuous iv infusion at a dose of 50 μg/kg per day or 100 μg/kg per day. Five patients with refractory breast cancer received treatment for from 6 to 8 days. Severe toxic effects, including marked fluid overload and debilitating sensorimotor neuropathies, occurred in most patients. Immunoperoxidase studies suggested that 260F9 monoclonal antibody targeting of the Schwann cells may have induced demyelination and subsequent neuropathy. This is the first report of a targeted toxic effect due to an immunoconjugate.

Original languageEnglish (US)
Pages (from-to)775-781
Number of pages7
JournalJournal of the National Cancer Institute
Volume81
Issue number10
DOIs
StatePublished - May 22 1989

Fingerprint

Immunotoxins
Monoclonal antibodies
Monoclonal Antibody
Poisons
Breast Cancer
Animals
Monoclonal Antibodies
Immunoconjugates
Breast Neoplasms
Ricin
Oncology
Schwann Cells
Demyelinating Diseases
Overload
Refractory materials
Dose
Cells
Fluid
Fluids
Cell

ASJC Scopus subject areas

  • Statistics, Probability and Uncertainty
  • Applied Mathematics
  • Physiology (medical)
  • Radiology Nuclear Medicine and imaging
  • Oncology
  • Cancer Research

Cite this

Phase I study of an anti-breast cancer immunotoxin by continuous infusion : Report of a targeted toxic effect not predicted by animal studies. / Gould, Bruce J.; Borowitz, Michael J.; Groves, Eric S.; Carter, Peter W.; Anthony, Douglas; Weiner, Louis M.; Frankel, Arthur E.

In: Journal of the National Cancer Institute, Vol. 81, No. 10, 22.05.1989, p. 775-781.

Research output: Contribution to journalArticle

Gould, Bruce J. ; Borowitz, Michael J. ; Groves, Eric S. ; Carter, Peter W. ; Anthony, Douglas ; Weiner, Louis M. ; Frankel, Arthur E. / Phase I study of an anti-breast cancer immunotoxin by continuous infusion : Report of a targeted toxic effect not predicted by animal studies. In: Journal of the National Cancer Institute. 1989 ; Vol. 81, No. 10. pp. 775-781.
@article{702d7493b8b846d0a9a3c9425a9cb269,
title = "Phase I study of an anti-breast cancer immunotoxin by continuous infusion: Report of a targeted toxic effect not predicted by animal studies",
abstract = "260F9 Monoclonal antibody-recombinant ricin A chain, an immunotoxin reactive with ≈50{\%} of breast carcinomas, was given by continuous iv infusion at a dose of 50 μg/kg per day or 100 μg/kg per day. Five patients with refractory breast cancer received treatment for from 6 to 8 days. Severe toxic effects, including marked fluid overload and debilitating sensorimotor neuropathies, occurred in most patients. Immunoperoxidase studies suggested that 260F9 monoclonal antibody targeting of the Schwann cells may have induced demyelination and subsequent neuropathy. This is the first report of a targeted toxic effect due to an immunoconjugate.",
author = "Gould, {Bruce J.} and Borowitz, {Michael J.} and Groves, {Eric S.} and Carter, {Peter W.} and Douglas Anthony and Weiner, {Louis M.} and Frankel, {Arthur E.}",
year = "1989",
month = "5",
day = "22",
doi = "10.1093/jnci/81.10.775",
language = "English (US)",
volume = "81",
pages = "775--781",
journal = "Journal of the National Cancer Institute",
issn = "0027-8874",
publisher = "Oxford University Press",
number = "10",

}

TY - JOUR

T1 - Phase I study of an anti-breast cancer immunotoxin by continuous infusion

T2 - Report of a targeted toxic effect not predicted by animal studies

AU - Gould, Bruce J.

AU - Borowitz, Michael J.

AU - Groves, Eric S.

AU - Carter, Peter W.

AU - Anthony, Douglas

AU - Weiner, Louis M.

AU - Frankel, Arthur E.

PY - 1989/5/22

Y1 - 1989/5/22

N2 - 260F9 Monoclonal antibody-recombinant ricin A chain, an immunotoxin reactive with ≈50% of breast carcinomas, was given by continuous iv infusion at a dose of 50 μg/kg per day or 100 μg/kg per day. Five patients with refractory breast cancer received treatment for from 6 to 8 days. Severe toxic effects, including marked fluid overload and debilitating sensorimotor neuropathies, occurred in most patients. Immunoperoxidase studies suggested that 260F9 monoclonal antibody targeting of the Schwann cells may have induced demyelination and subsequent neuropathy. This is the first report of a targeted toxic effect due to an immunoconjugate.

AB - 260F9 Monoclonal antibody-recombinant ricin A chain, an immunotoxin reactive with ≈50% of breast carcinomas, was given by continuous iv infusion at a dose of 50 μg/kg per day or 100 μg/kg per day. Five patients with refractory breast cancer received treatment for from 6 to 8 days. Severe toxic effects, including marked fluid overload and debilitating sensorimotor neuropathies, occurred in most patients. Immunoperoxidase studies suggested that 260F9 monoclonal antibody targeting of the Schwann cells may have induced demyelination and subsequent neuropathy. This is the first report of a targeted toxic effect due to an immunoconjugate.

UR - http://www.scopus.com/inward/record.url?scp=0024411071&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024411071&partnerID=8YFLogxK

U2 - 10.1093/jnci/81.10.775

DO - 10.1093/jnci/81.10.775

M3 - Article

C2 - 2785605

AN - SCOPUS:0024411071

VL - 81

SP - 775

EP - 781

JO - Journal of the National Cancer Institute

JF - Journal of the National Cancer Institute

SN - 0027-8874

IS - 10

ER -